신규 분자 실체 의약품 시장 보고서 : 동향, 예측, 경쟁 분석(-2031년)

The future of the global new molecular entity drug market looks promising with opportunities in the hospital and clinic markets. The global new molecular entity drug market is expected to grow with a CAGR of 5.1% from 2025 to 2031. The major drivers for this market are the increasing global burden of chronic conditions and the growing investments in pharmaceutical research.

• Lucintel forecasts that, within the type category, small molecule drugs are expected to witness the highest growth over the forecast period.
• Within the application category, hospitals are expected to witness the highest growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the New Molecular Entity Drug Market

The new molecular entity drug market is being shaped by several emerging trends, including technological advancements, evolving regulatory frameworks, and increased focus on personalized treatments. These trends are impacting how new drugs are developed, approved, and delivered to patients.

• Personalized Medicine: Personalized medicine is a key trend in the NME drug market, with an increasing focus on tailoring treatments based on individual genetic profiles and disease characteristics. This approach improves the efficacy of treatments by targeting the underlying causes of diseases, especially in oncology and rare genetic disorders. As a result, pharmaceutical companies are investing heavily in precision medicine, biomarker research, and companion diagnostics to develop targeted therapies. Personalized treatments also helps to minimize side effects and improve patient outcomes and satisfaction.
• Accelerated Regulatory Approvals: To address unmet medical needs, many countries, including the U.S., China, and Japan, are implementing faster regulatory pathways for NME drugs. Initiatives like the FDA's Breakthrough Therapy Designation and the EMA's PRIME program are designed to expedite the approval process for drugs that show significant promise in treating serious conditions. These regulatory changes are reducing the time it takes for new drugs to reach the market, benefiting both patients and pharmaceutical companies by speeding up access to innovative therapies and addressing global health challenges more efficiently.
• Biologics and Gene Therapy: The increasing use of biologics and gene therapies is transforming the NME drug market, as these therapies offer new treatment options for diseases that were once considered untreatable. Biologics, which include monoclonal antibodies, vaccines, and recombinant proteins, are becoming more prevalent in treating cancer, autoimmune diseases, and genetic disorders. Gene therapies are offering the potential to correct genetic mutations at the molecular level, providing long-term solutions for previously incurable conditions. This shift is expanding the scope of the NME drug market, creating new opportunities for companies in the biologics and gene therapy space.
• Integration of Artificial Intelligence (AI) and Machine Learning: AI and machine learning are increasingly being integrated into the NME drug discovery process. These technologies are helping researchers analyze large datasets, identify new drug targets, and predict the effectiveness of compounds more efficiently than traditional methods. AI is also being used to design clinical trials, improving the likelihood of success and minimizing costs. As AI technology evolves, its application in drug discovery and development is expected to reduce time-to-market and lead to more successful, targeted therapies for a range of diseases.
• Focus on Rare Diseases: There is a growing emphasis on developing new molecular entities to treat rare and orphan diseases, which often lack effective treatments. This trend is being driven by regulatory incentives, such as orphan drug designations, and increased research into the molecular mechanisms of these diseases. Pharmaceutical companies are recognizing the potential for both scientific and commercial success in addressing unmet needs in this underserved patient population. With advancements in gene therapies, biologics, and personalized medicine, there is significant potential for NME drugs to transform the treatment landscape for rare diseases.

These trends are revolutionizing the NME drug market by accelerating the development and approval of innovative therapies, improving the precision of treatments, and expanding access to novel treatments for rare diseases. Personalized medicine, accelerated regulatory approvals, and the use of AI are helping streamline the drug development process, while biologics and gene therapy are providing groundbreaking solutions for previously untreatable conditions. As these trends continue to evolve, they will reshape the pharmaceutical landscape, improving patient outcomes and driving market growth.

Recent Developments in the New Molecular Entity Drug Market

Several key developments have been shaping the new molecular entity drug market, driving innovation, and improving patient care in recent years.

• Approval of Breakthrough Cancer Therapies: One of the most significant recent developments in the NME drug market is the approval of several breakthrough cancer therapies, particularly in immuno-oncology. Drugs like immune checkpoint inhibitors and CAR T-cell therapies have revolutionized the treatment of various cancers. These therapies harness the body's immune system to fight cancer, offering hope for patients with advanced or refractory cancers. The approval of these innovative treatments has marked a new era in oncology, with promising results in clinical trials and growing adoption in clinical settings.
• Advances in mRNA-Based Vaccines: The COVID-19 pandemic highlighted the potential of mRNA technology, not only for vaccines but also for developing new molecular entities. Companies like Moderna and Pfizer have been pioneers in mRNA vaccine technology, and this approach is now being explored for other diseases, including cancer and rare genetic disorders. The success of mRNA vaccines has opened new avenues for NME drug development, allowing for rapid production and customization of therapies to target specific diseases at the molecular level.
• Focus on Alzheimer's Disease Treatments: There has been significant investment and research into developing NME drugs for Alzheimer's disease, driven by the growing need for treatments for neurodegenerative disorders. In recent years, several new molecular entities aimed at slowing the progression of Alzheimer's have received attention, including anti-amyloid beta therapies. While some of these therapies are still in the early stages, their approval would represent a major step forward in treating Alzheimer's, which has long lacked effective therapeutic options.
• Increased Investment in Biologics: Biologics are increasingly becoming a key focus of pharmaceutical companies developing NMEs. With biologics accounting for a growing share of new drug approvals, companies are expanding their pipelines to include monoclonal antibodies, gene therapies, and recombinant proteins. This focus on biologics is expected to drive the NME drug market forward, particularly in the areas of oncology, autoimmune diseases, and rare genetic disorders. The rise in biologics has also spurred advances in manufacturing and delivery methods, improving the accessibility of these high-cost treatments.
• Regulatory Changes to Speed Drug Approvals: Regulatory agencies in key markets, such as the FDA, EMA, and NMPA, have implemented several initiatives to expedite the approval of NMEs. Fast Track Designations, Breakthrough Therapy Designations, and Priority Review designations have allowed promising new drugs to reach the market more quickly. These regulatory changes are enabling patients to access innovative therapies sooner, reducing the time it takes for critical treatments to be available globally, and driving competition among pharmaceutical companies to develop the next generation of NME drugs.

Recent developments in the NME drug market have accelerated innovation, particularly in oncology, neurology, and rare diseases. The approval of breakthrough therapies, advances in mRNA technology, and the rise of biologics are expanding treatment options for patients worldwide. Regulatory changes have also sped up the process of getting new treatments to market, addressing unmet medical needs more efficiently. These developments are reshaping the NME drug market, improving the speed and precision with which new therapies are introduced to address complex diseases.

Strategic Growth Opportunities in the New Molecular Entity Drug Market

The new molecular entity drug market presents several strategic growth opportunities across various applications, with increasing demand for targeted and personalized therapies.

• Oncology Treatments: The oncology segment remains one of the most significant growth opportunities in the NME drug market. New molecular entities are revolutionizing cancer treatment, particularly through immunotherapy, targeted therapies, and personalized medicine. As cancer continues to be a leading cause of death worldwide, the demand for effective and innovative cancer treatments is high. Pharmaceutical companies are investing heavily in developing NMEs to address unmet needs in oncology, especially for rare and difficult-to-treat cancers.
• Rare and Orphan Diseases: There is a growing focus on developing NMEs for rare and orphan diseases, which often have limited treatment options. Regulatory incentives such as orphan drug designations are encouraging pharmaceutical companies to develop therapies for these underserved patient populations. Advances in gene therapies, biologics, and precision medicine are creating new opportunities to address complex diseases, offering hope for patients with previously untreatable conditions.
• Neurological Disorders: The neurological disorder segment is another key area of growth for the NME drug market. Diseases such as Alzheimer's, Parkinson's, and multiple sclerosis are gaining increased attention from researchers and drug developers. The aging global population and the lack of effective treatments for many neurological conditions create a substantial market opportunity. Innovations in gene therapy, biologics, and targeted small molecules are driving growth in this sector.
• Infectious Diseases: The rise in antimicrobial resistance and the growing demand for new treatments for infectious diseases create significant opportunities in the NME drug market. With the COVID-19 pandemic underscoring the importance of rapid drug development and global collaboration, the focus on developing NMEs for infectious diseases has intensified. Companies are exploring new mechanisms of action, such as antiviral and antibacterial-resistant drugs, to address emerging global health threats.
• Personalized Medicine and Precision Therapies: The increasing shift toward personalized medicine presents a significant growth opportunity for the NME drug market. With the help of biomarkers, genetic testing, and AI-driven tools, pharmaceutical companies can develop tailored therapies that address individual patient profiles. This approach is particularly promising in oncology, rare diseases, and autoimmune conditions. Personalized medicine allows for more effective treatments with fewer side effects, providing long-term value for both patients and healthcare systems.

The strategic growth opportunities in the NME drug market are driven by the demand for innovative therapies in oncology, rare diseases, neurological disorders, and infectious diseases. Advances in personalized medicine and precision therapies are expanding treatment options and improving patient outcomes. These opportunities are reshaping the pharmaceutical industry, driving innovation and investment in the development of next-generation treatments that address complex and previously untreatable diseases.

New Molecular Entity Drug Market Driver and Challenges

The NME drug market is influenced by a variety of drivers and challenges, which include technological, economic, and regulatory factors.

The factors responsible for driving the new molecular entity drug market include:

1. Advancements in Biotechnology: Biotechnology innovations, particularly in gene editing and biologics, are driving the NME drug market forward. New technologies such as CRISPR and RNA-based therapies are enabling the development of novel treatments for complex diseases, paving the way for next-generation drugs. These advancements are helping pharmaceutical companies create more effective, targeted therapies that improve patient outcomes.

2. Increased Research and Development Investment: Significant investment in research and development (R&D) is fueling innovation in the NME drug market. Pharmaceutical companies, particularly biotech firms, are investing heavily in exploring new drug discovery approaches, clinical trials, and collaboration with research institutions. This increased investment is accelerating the development of novel treatments and expanding the drug pipeline.

3. Regulatory Support for Innovation: Regulatory agencies in key markets are supporting the development of innovative drugs through expedited approval pathways, such as the FDA's Breakthrough Therapy Designation and the EMA's PRIME program. These regulatory measures help reduce time-to-market for NME drugs, providing faster access to life-saving treatments for patients in need.

4. Growing Global Healthcare Demand: The increasing demand for healthcare services, driven by aging populations, chronic disease burdens, and emerging health threats like infectious diseases, is fueling the demand for new drugs. The global healthcare market is expanding, and NME drugs are at the forefront of meeting these needs, especially in underserved regions.

5. Collaborations and Partnerships: Collaborations between pharmaceutical companies, academic institutions, and healthcare providers are enabling faster drug discovery and development. By pooling resources and expertise, stakeholders can accelerate clinical trials, share research data, and bring new drugs to market more efficiently. These partnerships are essential for advancing the NME drug pipeline.

Challenges in the new molecular entity drug market are:

1. High Development Costs: The development of new molecular entities is expensive and time-consuming. Clinical trials, regulatory approvals, and the need for specialized expertise all contribute to the high costs associated with developing NMEs. This can limit the ability of smaller companies to compete and may delay the introduction of new treatments.

2. Market Access Barriers: Despite regulatory approvals, market access barriers, including pricing and reimbursement challenges, can hinder the availability of NME drugs. In many cases, the high cost of innovative therapies can limit their affordability and accessibility, particularly in low- and middle-income countries.

3. Complexity of Clinical Trials: The complexity of designing and conducting clinical trials, particularly for rare diseases and personalized medicine, presents a significant challenge in the NME drug market. Recruiting patients, managing diverse study populations, and ensuring rigorous trial methodologies require significant resources and time.

While drivers such as technological advancements, R&D investment, and regulatory support are fueling growth in the NME drug market, challenges like high costs, market access barriers, and clinical trial complexities remain key obstacles. Overcoming these challenges will be crucial to ensuring continued innovation and accessibility in the NME drug market.

List of New Molecular Entity Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies new molecular entity drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the new molecular entity drug companies profiled in this report include-

• UCB
• Otsuka Pharmaceutical
• Eli Lilly
• Genentech
• Eisai
• Biogen
• Menarini Group
• GSK
• Chest
• Travere

New Molecular Entity Drug Market by Segment

The study includes a forecast for the global new molecular entity drug market by type, application, and region.

New Molecular Entity Drug Market by Type [Value from 2019 to 2031]:

• Antibody
• Polypeptide
• Small Molecule Drug
• Other

New Molecular Entity Drug Market by Application [Value from 2019 to 2031]:

• Hospitals
• Clinics

New Molecular Entity Drug Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the New Molecular Entity Drug Market

The new molecular entity drug market has been undergoing significant growth due to advancements in biotechnology, precision medicine, and an increased understanding of disease mechanisms. These drugs are critical in treating conditions that have limited therapeutic options. With an emphasis on personalized treatment, the market in countries like the United States, China, Germany, India, and Japan is experiencing rapid innovation. Regulatory agencies, industry collaborations, and research institutions are playing pivotal roles in accelerating the discovery and approval of these groundbreaking treatments, impacting both healthcare systems and patient outcomes.

• United States: The United States remains at the forefront of NME drug development, with a significant number of new molecular entities being approved by the U.S. Food and Drug Administration (FDA). Key therapeutic areas such as oncology, immunology, and neurology are seeing rapid advancements in NME treatments. The FDA's expedited approval pathways, such as Breakthrough Therapy and Accelerated Approval, have been instrumental in bringing innovative treatments to market faster. Additionally, the growing emphasis on personalized medicine and biologics is driving innovation in the U.S. NME drug market, with many biotech firms focusing on targeted therapies for rare diseases and cancer.
• China: China's pharmaceutical industry has seen substantial growth in recent years, with a strong focus on developing and commercializing new molecular entities. The country has made significant strides in regulatory reform, with the China National Medical Products Administration (NMPA) accelerating drug approval processes, leading to an increase in NME drug launches. Areas like oncology, diabetes, and cardiovascular diseases are seeing increasing numbers of new drugs entering the market. China is also becoming a hub for clinical trials, with multinational pharmaceutical companies leveraging the country's vast population to test new drugs, facilitating faster approval and commercialization.
• Germany: Germany, as a leader in Europe, has been making notable progress in the NME drug market, particularly in oncology, immunology, and rare diseases. The country's robust healthcare infrastructure, strong regulatory environment, and innovative biotech companies have contributed to the rapid development of new drugs. The European Medicines Agency (EMA) has played a vital role in expediting approvals within the EU, with Germany benefiting from these initiatives. Moreover, Germany's emphasis on precision medicine and its investment in research collaborations with academic institutions and global pharmaceutical companies is helping shape the future of NME drug development in the region.
• India: The Indian NME drug market is seeing rapid growth due to an increasing focus on research and development (R&D) and the country's growing biotech ecosystem. Indian pharmaceutical companies are increasingly involved in the development of new molecular entities, particularly for treating infectious diseases, cancer, and diabetes. The Indian government's initiatives, such as the "Pharma Vision 2020," aim to boost the country's pharmaceutical R&D capabilities. Additionally, India is playing a crucial role in the global supply chain, with a growing number of clinical trials being conducted in the country, contributing to NME drug discovery and development.
• Japan: Japan is a key player in the NME drug market, with strong government support for pharmaceutical innovation. The Japanese Ministry of Health, Labour, and Welfare (MHLW) has created a favorable environment for drug approval with initiatives such as the Sakigake Designation System, which accelerates the development of innovative drugs. Japan's aging population is a key driver for the demand for NME drugs, especially in the fields of oncology, neurodegenerative diseases, and cardiovascular disorders. Additionally, Japan is home to several global pharmaceutical companies that are investing in cutting-edge research and clinical trials to develop new drugs that address unmet medical needs.

Features of the Global New Molecular Entity Drug Market

• Market Size Estimates: New molecular entity drug market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: New molecular entity drug market size by type, application, and region in terms of value ($B).
• Regional Analysis: New molecular entity drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the new molecular entity drug market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the new molecular entity drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the new molecular entity drug market by type (antibody, polypeptide, small molecule drug, and other), application (hospitals and clinics), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global New Molecular Entity Drug Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Antibody: Trends and Forecast (2019-2031)
• 4.4 Polypeptide: Trends and Forecast (2019-2031)
• 4.5 Small Molecule Drug: Trends and Forecast (2019-2031)
• 4.6 Other: Trends and Forecast (2019-2031)

5. Global New Molecular Entity Drug Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Hospitals: Trends and Forecast (2019-2031)
• 5.4 Clinics: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global New Molecular Entity Drug Market by Region

7. North American New Molecular Entity Drug Market

• 7.1 Overview
• 7.2 North American New Molecular Entity Drug Market by Type
• 7.3 North American New Molecular Entity Drug Market by Application
• 7.4 United States New Molecular Entity Drug Market
• 7.5 Mexican New Molecular Entity Drug Market
• 7.6 Canadian New Molecular Entity Drug Market

8. European New Molecular Entity Drug Market

• 8.1 Overview
• 8.2 European New Molecular Entity Drug Market by Type
• 8.3 European New Molecular Entity Drug Market by Application
• 8.4 German New Molecular Entity Drug Market
• 8.5 French New Molecular Entity Drug Market
• 8.6 Spanish New Molecular Entity Drug Market
• 8.7 Italian New Molecular Entity Drug Market
• 8.8 United Kingdom New Molecular Entity Drug Market

9. APAC New Molecular Entity Drug Market

• 9.1 Overview
• 9.2 APAC New Molecular Entity Drug Market by Type
• 9.3 APAC New Molecular Entity Drug Market by Application
• 9.4 Japanese New Molecular Entity Drug Market
• 9.5 Indian New Molecular Entity Drug Market
• 9.6 Chinese New Molecular Entity Drug Market
• 9.7 South Korean New Molecular Entity Drug Market
• 9.8 Indonesian New Molecular Entity Drug Market

10. ROW New Molecular Entity Drug Market

• 10.1 Overview
• 10.2 ROW New Molecular Entity Drug Market by Type
• 10.3 ROW New Molecular Entity Drug Market by Application
• 10.4 Middle Eastern New Molecular Entity Drug Market
• 10.5 South American New Molecular Entity Drug Market
• 10.6 African New Molecular Entity Drug Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global New Molecular Entity Drug Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 UCB
  • Company Overview
  • New Molecular Entity Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Otsuka Pharmaceutical
  • Company Overview
  • New Molecular Entity Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Eli Lilly
  • Company Overview
  • New Molecular Entity Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Genentech
  • Company Overview
  • New Molecular Entity Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Eisai
  • Company Overview
  • New Molecular Entity Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 Biogen
  • Company Overview
  • New Molecular Entity Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Menarini Group
  • Company Overview
  • New Molecular Entity Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.9 GSK
  • Company Overview
  • New Molecular Entity Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.10 Chest
  • Company Overview
  • New Molecular Entity Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.11 Travere
  • Company Overview
  • New Molecular Entity Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us